- Home
- YOUL vs ATRA Comparison
YOUL vs ATRA Comparison
Compare YOUL & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YOUL | ATRA |
|---|---|---|
| Founded | N/A | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.6M | 129.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | YOUL | ATRA |
|---|---|---|
| Price | $1.52 | $16.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | N/A | ★ 74.4K |
| Earning Date | N/A | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.97 |
| Revenue | N/A | ★ $151,930,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.79 |
| Revenue Growth | N/A | ★ 51.27 |
| 52 Week Low | N/A | $5.01 |
| 52 Week High | N/A | $18.95 |
Technical Indicators
Market Signals| Indicator | YOUL | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 57.89 |
| Support Level | N/A | $16.51 |
| Resistance Level | N/A | $18.95 |
| Average True Range (ATR) | 0.00 | 1.37 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 59.80 |
Price Performance
Historical ComparisonAbout YOUL Youlife Group Inc. American Depositary Shares
Youlife Group Inc is a blue-collar lifetime service provider with a nationwide network of 25 vocational schools under school management model and 25 curriculum development projects, covering a total of 37 cities or counties under 16 provinces of China.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).